Trio begins TB vaccine ramp-up

Work is underway to develop manufacturing methods for the scale-up of a mycobacterium vaccine to treat tuberculosis in new HIV/AIDS patients in developing countries. The ramp-up effort follows a positive outcome in clinical trials of HIV-infected people in Tanzania: The MV vaccine reduced their rate of tuberculosis by more than one-third.

The current manufacturing activities aim to set processes and procedures for the production of large quantities of the inactivated, whole-cell mycobacterial vaccine for additional studies and clinical use. A chief objective is making the vaccine economical to produce and distribute in infrastructure-poor areas.

Manufacturing development will be conducted by the Aeras Global TB Vaccine Foundation in conjunction with London-based Immodulon Therapeutics. Dartmouth Medical School researchers drove development of the vaccine.

Those newly infected with HIV risk contracting TB almost immediately, say Dartmouth researchers. The MV vaccine is being hailed as the first to demonstrate that any type of vaccine can prevent an infectious complication of HIV in adults.

- see the article

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.